Skip to main content
. 2021 Mar 5;13(5):1123. doi: 10.3390/cancers13051123

Figure 1.

Figure 1

Treatment of patients with CAR immune cells. In the first step, immune cells are isolated from the patient’s blood by leukapheresis. These autologous immune cells are then manufactured off-site and genetically modified to target and kill antigen carrying cancer cells. The treatment is initiated by intravenous infusion of CAR immune cells into the patient.